<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/mostaccessed/journal?journal=bmcmedgenomics&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Medical Genomics - Most accessed articles</title>
        <link>http://www.biomedcentral.com/bmcmedgenomics/</link>
        <description>The most accessed research articles published by BMC Medical Genomics</description>
        <dc:date>2009-11-10T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1755-8794/2/2" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1755-8794/2/64" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1755-8794/2/65" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1755-8794/2/61" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1755-8794/2/62" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1755-8794/2/59" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1755-8794/2/37" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1755-8794/2/54" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1755-8794/2/56" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1755-8794/2/58" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1755-8794/2/2">
        <title>Iron behaving badly: inappropriate Iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases</title>
        <description>Background:
The production of peroxide and superoxide is an inevitable consequence of aerobic metabolism, and while these particular &apos;reactive oxygen species&apos; (ROSs) can exhibit a number of biological effects, they are not of themselves excessively reactive and thus they are not especially damaging at physiological concentrations. However, their reactions with poorly liganded iron species can lead to the catalytic production of the very reactive and dangerous hydroxyl radical, which is exceptionally damaging, and a major cause of chronic inflammation.ReviewWe review the considerable and wide-ranging evidence for the involvement of this combination of (su)peroxide and poorly liganded iron in a large number of physiological and indeed pathological processes and inflammatory disorders, especially those involving the progressive degradation of cellular and organismal performance. These diseases share a great many similarities and thus might be considered to have a common cause (i.e. iron-catalysed free radical and especially hydroxyl radical generation).The studies reviewed include those focused on a series of cardiovascular, metabolic and neurological diseases, where iron can be found at the sites of plaques and lesions, as well as studies showing the significance of iron to aging and longevity. The effective chelation of iron by natural or synthetic ligands is thus of major physiological (and potentially therapeutic) importance. As systems properties, we need to recognise that physiological observables have multiple molecular causes, and studying them in isolation leads to inconsistent patterns of apparent causality when it is the simultaneous combination of multiple factors that is responsible.This explains, for instance, the decidedly mixed effects of antioxidants that have been observed, since in some circumstances (especially the presence of poorly liganded iron) molecules that are nominally antioxidants can actually act as pro-oxidants. The reduction of redox stress thus requires suitable levels of both antioxidants and effective iron chelators. Some polyphenolic antioxidants may serve both roles.Understanding the exact speciation and liganding of iron in all its states is thus crucial to separating its various pro- and anti-inflammatory activities. Redox stress, innate immunity and pro- (and some anti-)inflammatory cytokines are linked in particular via signalling pathways involving NF-kappaB and p38, with the oxidative roles of iron here seemingly involved upstream of the IkappaB kinase (IKK) reaction. In a number of cases it is possible to identify mechanisms by which ROSs and poorly liganded iron act synergistically and autocatalytically, leading to &apos;runaway&apos; reactions that are hard to control unless one tackles multiple sites of action simultaneously. Some molecules such as statins and erythropoietin, not traditionally associated with anti-inflammatory activity, do indeed have &apos;pleiotropic&apos; anti-inflammatory effects that may be of benefit here.
Conclusion:
Overall we argue, by synthesising a widely dispersed literature, that the role of poorly liganded iron has been rather underappreciated in the past, and that in combination with peroxide and superoxide its activity underpins the behaviour of a great many physiological processes that degrade over time. Understanding these requires an integrative, systems-level approach that may lead to novel therapeutic targets.</description>
        <link>http://www.biomedcentral.com/1755-8794/2/2</link>
                <dc:creator>Douglas Kell</dc:creator>
                <dc:source>BMC Medical Genomics 2009, 2:2</dc:source>
        <dc:date>2009-01-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-8794-2-2</dc:identifier>
        <prism:publicationName>BMC Medical Genomics</prism:publicationName>
        <prism:issn>1755-8794</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2009-01-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1755-8794/2/64">
        <title>Accurate molecular classification of cancer using simple rules</title>
        <description>Background:
One intractable problem with using microarray data analysis for cancer classification is how to reduce the extremely high-dimensionality gene feature data to remove the effects of noise. Feature selection is often used to address this problem by selecting informative genes from among thousands or tens of thousands of genes. However, most of the existing methods of microarray-based cancer classification utilize too many genes to achieve accurate classification, which often hampers the interpretability of the models. For a better understanding of the classification results, it is desirable to develop simpler rule-based models with as few marker genes as possible.
Methods:
We screened a small number of informative single genes and gene pairs on the basis of their depended degrees proposed in rough sets. Applying the decision rules induced by the selected genes or gene pairs, we constructed cancer classifiers. We tested the efficacy of the classifiers by leave-one-out cross-validation (LOOCV) of training sets and classification of independent test sets.
Results:
We applied our methods to five cancerous gene expression datasets: leukemia (acute lymphoblastic leukemia [ALL] vs. acute myeloid leukemia [AML]), lung cancer, prostate cancer, breast cancer, and leukemia (ALL vs. mixed-lineage leukemia [MLL] vs. AML). Accurate classification outcomes were obtained by utilizing just one or two genes. Some genes that correlated closely with the pathogenesis of relevant cancers were identified. In terms of both classification performance and algorithm simplicity, our approach outperformed or at least matched existing methods.
Conclusion:
In cancerous gene expression datasets, a small number of genes, even one or two if selected correctly, is capable of achieving an ideal cancer classification effect. This finding also means that very simple rules may perform well for cancerous class prediction.</description>
        <link>http://www.biomedcentral.com/1755-8794/2/64</link>
                <dc:creator>Xiaosheng Wang</dc:creator>
                <dc:creator>Osamu Gotoh</dc:creator>
                <dc:source>BMC Medical Genomics 2009, 2:64</dc:source>
        <dc:date>2009-10-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-8794-2-64</dc:identifier>
        <prism:publicationName>BMC Medical Genomics</prism:publicationName>
        <prism:issn>1755-8794</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>64</prism:startingPage>
        <prism:publicationDate>2009-10-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1755-8794/2/65">
        <title>Gene expression profiling in sinonasal adenocarcinoma</title>
        <description>Background:
Sinonasal adenocarcinomas are uncommon tumors which develop in the ethmoid sinus after exposure to wood dust. Although the etiology of these tumors is well defined, very little is known about their molecular basis and no diagnostic tool exists for their early detection in high-risk workers.
Methods:
To identify genes involved in this disease, we performed gene expression profiling using cancer-dedicated microarrays, on nine matched samples of sinonasal adenocarcinomas and non-tumor sinusal tissue. Microarray results were validated by quantitative RT-PCR and immunohistochemistry on two additional sets of tumors.
Results:
Among the genes with significant differential expression we selected LGALS4, ACS5, CLU, SRI and CCT5 for further exploration. The overexpression of LGALS4, ACS5, SRI, CCT5 and the downregulation of CLU were confirmed by quantitative RT-PCR. Immunohistochemistry was performed for LGALS4 (Galectin 4), ACS5 (Acyl-CoA synthetase) and CLU (Clusterin) proteins: LGALS4 was highly up-regulated, particularly in the most differentiated tumors, while CLU was lost in all tumors. The expression of ACS5, was more heterogeneous and no correlation was observed with the tumor type.
Conclusion:
Within our microarray study in sinonasal adenocarcinoma we identified two proteins, LGALS4 and CLU, that were significantly differentially expressed in tumors compared to normal tissue. A further evaluation on a new set of tissues, including precancerous stages and low grade tumors, is necessary to evaluate the possibility of using them as diagnostic markers.</description>
        <link>http://www.biomedcentral.com/1755-8794/2/65</link>
                <dc:creator>Dominique Tripodi</dc:creator>
                <dc:creator>Sylvia Quemener</dc:creator>
                <dc:creator>Karine Renaudin</dc:creator>
                <dc:creator>Christophe Ferron</dc:creator>
                <dc:creator>Olivier Malard</dc:creator>
                <dc:creator>Isabelle Guisle-Marsollier</dc:creator>
                <dc:creator>Veronique Sebille-Rivain</dc:creator>
                <dc:creator>Christian Verger</dc:creator>
                <dc:creator>Christian Geraut</dc:creator>
                <dc:creator>Catherine Gratas-Rabbia-Re</dc:creator>
                <dc:source>BMC Medical Genomics 2009, 2:65</dc:source>
        <dc:date>2009-11-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-8794-2-65</dc:identifier>
        <prism:publicationName>BMC Medical Genomics</prism:publicationName>
        <prism:issn>1755-8794</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>65</prism:startingPage>
        <prism:publicationDate>2009-11-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1755-8794/2/61">
        <title>Discovering cancer genes by integrating network and functional properties</title>
        <description>Background:
Identification of novel cancer-causing genes is one of the main goals in cancer research. The rapid accumulation of genome-wide protein-protein interaction (PPI) data in humans has provided a new basis for studying the topological features of cancer genes in cellular networks. It is important to integrate multiple genomic data sources, including PPI networks, protein domains and Gene Ontology (GO) annotations, to facilitate the identification of cancer genes.
Methods:
Topological features of the PPI network, as well as protein domain compositions, enrichment of gene ontology categories, sequence and evolutionary conservation features were extracted and compared between cancer genes and other genes. The predictive power of various classifiers for identification of cancer genes was evaluated by cross validation. Experimental validation of a subset of the prediction results was conducted using siRNA knockdown and viability assays in human colon cancer cell line DLD-1.
Results:
Cross validation demonstrated advantageous performance of classifiers based on support vector machines (SVMs) with the inclusion of the topological features from the PPI network, protein domain compositions and GO annotations. We then applied the trained SVM classifier to human genes to prioritize putative cancer genes. siRNA knock-down of several SVM predicted cancer genes displayed greatly reduced cell viability in human colon cancer cell line DLD-1.
Conclusion:
Topological features of PPI networks, protein domain compositions and GO annotations are good predictors of cancer genes. The SVM classifier integrates multiple features and as such is useful for prioritizing candidate cancer genes for experimental validations.</description>
        <link>http://www.biomedcentral.com/1755-8794/2/61</link>
                <dc:creator>Li Li</dc:creator>
                <dc:creator>Kangyu Zhang</dc:creator>
                <dc:creator>James Lee</dc:creator>
                <dc:creator>Shaun Cordes</dc:creator>
                <dc:creator>David Davis</dc:creator>
                <dc:creator>Zhijun Tang</dc:creator>
                <dc:source>BMC Medical Genomics 2009, 2:61</dc:source>
        <dc:date>2009-09-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-8794-2-61</dc:identifier>
        <prism:publicationName>BMC Medical Genomics</prism:publicationName>
        <prism:issn>1755-8794</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>61</prism:startingPage>
        <prism:publicationDate>2009-09-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1755-8794/2/62">
        <title>Exon expression in lymphoblastoid cell lines from subjects with schizophrenia before and after glucose deprivation</title>
        <description>Background:
The purpose of this study was to examine the effects of glucose reduction stress on lymphoblastic cell line (LCL) gene expression in subjects with schizophrenia compared to non-psychotic relatives.
Methods:
LCLs were grown under two glucose conditions to measure the effects of glucose reduction stress on exon expression in subjects with schizophrenia compared to unaffected family member controls. A second aim of this project was to identify cis-regulated transcripts associated with diagnosis.
Results:
There were a total of 122 transcripts with significant diagnosis by probeset interaction effects and 328 transcripts with glucose deprivation by probeset interaction probeset effects after corrections for multiple comparisons. There were 8 transcripts with expression significantly affected by the interaction between diagnosis and glucose deprivation and probeset after correction for multiple comparisons. The overall validation rate by qPCR of 13 diagnosis effect genes identified through microarray was 62%, and all genes tested by qPCR showed concordant up- or down-regulation by qPCR and microarray. We assessed brain gene expression of five genes found to be altered by diagnosis and glucose deprivation in LCLs and found a significant decrease in expression of one gene, glutaminase, in the dorsolateral prefrontal cortex (DLPFC). One SNP with previously identified regulation by a 3&apos; UTR SNP was found to influence IRF5 expression in both brain and lymphocytes. The relationship between the 3&apos; UTR rs10954213 genotype and IRF5 expression was significant in LCLs (p = 0.0001), DLPFC (p = 0.007), and anterior cingulate cortex (p = 0.002).
Conclusion:
Experimental manipulation of cells lines from subjects with schizophrenia may be a useful approach to explore stress related gene expression alterations in schizophrenia and to identify SNP variants associated with gene expression.</description>
        <link>http://www.biomedcentral.com/1755-8794/2/62</link>
                <dc:creator>Maureen Martin</dc:creator>
                <dc:creator>Brandi Rollins</dc:creator>
                <dc:creator>P. Adolpho Sequeira</dc:creator>
                <dc:creator>Andrea Mesen</dc:creator>
                <dc:creator>William Byerley</dc:creator>
                <dc:creator>Richard Stein</dc:creator>
                <dc:creator>Emily Moon</dc:creator>
                <dc:creator>Huda Akil</dc:creator>
                <dc:creator>Edward Jones</dc:creator>
                <dc:creator>Stanley Watson</dc:creator>
                <dc:creator>Jack Barchas</dc:creator>
                <dc:creator>Lynn DeLisi</dc:creator>
                <dc:creator>Richard Myers</dc:creator>
                <dc:creator>Alan Schatzberg</dc:creator>
                <dc:creator>William Bunney</dc:creator>
                <dc:creator>Marquis Vawter</dc:creator>
                <dc:source>BMC Medical Genomics 2009, 2:62</dc:source>
        <dc:date>2009-09-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-8794-2-62</dc:identifier>
        <prism:publicationName>BMC Medical Genomics</prism:publicationName>
        <prism:issn>1755-8794</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>62</prism:startingPage>
        <prism:publicationDate>2009-09-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1755-8794/2/59">
        <title>Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family </title>
        <description>Background:
Pathway discovery from gene expression data can provide important insight into the relationship between signaling networks and cancer biology. Oncogenic signaling pathways are commonly inferred by comparison with signatures derived from cell lines. We use the Molecular Apocrine subtype of breast cancer to demonstrate our ability to infer pathways directly from patients&apos; gene expression data with pattern analysis algorithms.
Methods:
We combine data from two studies that propose the existence of the Molecular Apocrine phenotype. We use quantile normalization and XPN to minimize institutional bias in the data. We use hierarchical clustering, principal components analysis, and comparison of gene signatures derived from Significance Analysis of Microarrays to establish the existence of the Molecular Apocrine subtype and the equivalence of its molecular phenotype across both institutions. Statistical significance was computed using the Fasano &amp; Franceschini test for separation of principal components and the hypergeometric probability formula for significance of overlap in gene signatures. We perform pathway analysis using LeFEminer and Backward Chaining Rule Induction to identify a signaling network that differentiates the subset. We identify a larger cohort of samples in the public domain, and use Gene Shaving and Robust Bayesian Network Analysis to detect pathways that interact with the defining signal.
Results:
We demonstrate that the two separately introduced ER- breast cancer subsets represent the same tumor type, called Molecular Apocrine breast cancer. LeFEminer and Backward Chaining Rule Induction support a role for AR signaling as a pathway that differentiates this subset from others. Gene Shaving and Robust Bayesian Network Analysis detect interactions between the AR pathway, EGFR trafficking signals, and ErbB2.
Conclusion:
We propose criteria for meta-analysis that are able to demonstrate statistical significance in establishing molecular equivalence of subsets across institutions. Data mining strategies used here provide an alternative method to comparison with cell lines for discovering seminal pathways and interactions between signaling networks. Analysis of Molecular Apocrine breast cancer implies that therapies targeting AR might be hampered if interactions with ErbB family members are not addressed.</description>
        <link>http://www.biomedcentral.com/1755-8794/2/59</link>
                <dc:creator>Sandeep Sanga</dc:creator>
                <dc:creator>Bradley Broom</dc:creator>
                <dc:creator>Vittorio Cristini</dc:creator>
                <dc:creator>Mary Edgerton</dc:creator>
                <dc:source>BMC Medical Genomics 2009, 2:59</dc:source>
        <dc:date>2009-09-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-8794-2-59</dc:identifier>
        <prism:publicationName>BMC Medical Genomics</prism:publicationName>
        <prism:issn>1755-8794</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>59</prism:startingPage>
        <prism:publicationDate>2009-09-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1755-8794/2/37">
        <title>Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer</title>
        <description>Background:
Within estrogen receptor-positive breast cancer (ER+ BC), the expression levels of proliferation-related genes can define two clinically distinct molecular subtypes. When treated with adjuvant tamoxifen, those ER+ BCs that are lowly proliferative have a good prognosis (luminal-A subtype), however the clinical outcome of those that are highly proliferative is poor (luminal-B subtype).
Methods:
To investigate the biological basis for these observations, gene set enrichment analysis (GSEA) was performed using microarray data from 246 ER+ BC samples from women treated with adjuvant tamoxifen monotherapy. To create an in vitro model of growth factor (GF) signaling activation, MCF-7 cells were treated with heregulin (HRG), an HER3 ligand.
Results:
We found that a gene set linked to GF signaling was significantly enriched in the luminal-B tumors, despite only 10% of samples over-expressing HER2 by immunohistochemistry. To determine the biological significance of this observation, MCF-7 cells were treated with HRG. These cells displayed phosphorylation of HER2/3 and downstream ERK and S6. Treatment with HRG overcame tamoxifen-induced cell cycle arrest with higher S-phase fraction and increased anchorage independent colony formation. Gene expression profiles of MCF-7 cells treated with HRG confirmed enrichment of the GF signaling gene set and a similar proliferative signature observed in human ER+ BCs resistant to tamoxifen.
Conclusion:
These data demonstrate that activation of GF signaling pathways, independent of HER2 over-expression, could be contributing to the poor prognosis of the luminal-B ER+ BC subtype.</description>
        <link>http://www.biomedcentral.com/1755-8794/2/37</link>
                <dc:creator>Sherene Loi</dc:creator>
                <dc:creator>Christos Sotiriou</dc:creator>
                <dc:creator>Benjamin Haibe-Kains</dc:creator>
                <dc:creator>Francoise Lallemand</dc:creator>
                <dc:creator>Nelly Conus</dc:creator>
                <dc:creator>Martine Piccart</dc:creator>
                <dc:creator>Terence Speed</dc:creator>
                <dc:creator>Grant McArthur</dc:creator>
                <dc:source>BMC Medical Genomics 2009, 2:37</dc:source>
        <dc:date>2009-06-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-8794-2-37</dc:identifier>
        <prism:publicationName>BMC Medical Genomics</prism:publicationName>
        <prism:issn>1755-8794</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>37</prism:startingPage>
        <prism:publicationDate>2009-06-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1755-8794/2/54">
        <title>MicroRNA-125a is over-expressed in insulin target tissues in a spontaneous rat model of Type 2 Diabetes</title>
        <description>Background:
MicroRNAs (miRNAs) are non-coding RNA molecules involved in post-transcriptional control of gene expression of a wide number of genes, including those involved in glucose homeostasis. Type 2 diabetes (T2D) is characterized by hyperglycaemia and defects in insulin secretion and action at target tissues. We sought to establish differences in global miRNA expression in two insulin-target tissues from inbred rats of spontaneously diabetic and normoglycaemic strains.
Methods:
We used a miRNA microarray platform to measure global miRNA expression in two insulin-target tissues: liver and adipose tissue from inbred rats of spontaneously diabetic (Goto-Kakizaki [GK]) and normoglycaemic (Brown-Norway [BN]) strains which are extensively used in genetic studies of T2D. MiRNA data were integrated with gene expression data from the same rats to investigate how differentially expressed miRNAs affect the expression of predicted target gene transcripts.
Results:
The expression of 170 miRNAs was measured in liver and adipose tissue of GK and BN rats. Based on a p-value for differential expression between GK and BN, the most significant change in expression was observed for miR-125a in liver (FC = 5.61, P = 0.001, Padjusted = 0.10); this overexpression was validated using quantitative RT-PCR (FC = 13.15, P = 0.0005). MiR-125a also showed over-expression in the GK vs. BN analysis within adipose tissue (FC = 1.97, P = 0.078, Padjusted = 0.99), as did the previously reported miR-29a (FC = 1.51, P = 0.05, Padjusted = 0.99). In-silico tools assessing the biological role of predicted miR-125a target genes suggest an over-representation of genes involved in the MAPK signaling pathway. Gene expression analysis identified 1308 genes with significantly different expression between GK and BN rats (Padjusted &lt; 0.05): 233 in liver and 1075 in adipose tissue. Pathways related to glucose and lipid metabolism were significantly over-represented among these genes. Enrichment analysis suggested that differentially expressed genes in GK compared to BN included more predicted miR-125a target genes than would be expected by chance in adipose tissue (FDR = 0.006 for up-regulated genes; FDR = 0.036 for down-regulated genes) but not in liver (FDR = 0.074 for up-regulated genes; FDR = 0.248 for down-regulated genes).
Conclusion:
MiR-125a is over-expressed in liver in hyperglycaemic GK rats relative to normoglycaemic BN rats, and our array data also suggest miR-125a is over-expressed in adipose tissue. We demonstrate the use of in-silico tools to provide the basis for further investigation of the potential role of miR-125a in T2D. In particular, the enrichment of predicted miR-125a target genes among differentially expressed genes has identified likely target genes and indicates that integrating global miRNA and mRNA expression data may give further insights into miRNA-mediated regulation of gene expression.</description>
        <link>http://www.biomedcentral.com/1755-8794/2/54</link>
                <dc:creator>Blanca Herrera</dc:creator>
                <dc:creator>Helen Lockstone</dc:creator>
                <dc:creator>Jennifer Taylor</dc:creator>
                <dc:creator>Quin Wills</dc:creator>
                <dc:creator>Pamela Kaisaki</dc:creator>
                <dc:creator>Amy Barrett</dc:creator>
                <dc:creator>Carme Camps</dc:creator>
                <dc:creator>Cristina Fernandez</dc:creator>
                <dc:creator>Jiannis Ragoussis</dc:creator>
                <dc:creator>Dominique Gauguier</dc:creator>
                <dc:creator>Mark McCarthy</dc:creator>
                <dc:creator>Cecilia Lindgren</dc:creator>
                <dc:source>BMC Medical Genomics 2009, 2:54</dc:source>
        <dc:date>2009-08-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-8794-2-54</dc:identifier>
        <prism:publicationName>BMC Medical Genomics</prism:publicationName>
        <prism:issn>1755-8794</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>54</prism:startingPage>
        <prism:publicationDate>2009-08-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1755-8794/2/56">
        <title>Induction of the interleukin 6/ signal transducer and activator of transcription pathway in the lungs of mice sub-chronically exposed to mainstream tobacco smoke.</title>
        <description>Background:
Tobacco smoking is associated with lung cancer and other respiratory diseases. However, little is known about the global molecular changes that precede the appearance of clinically detectable symptoms. In this study, the effects of mainstream tobacco smoke (MTS) on global transcription in the mouse lung were investigated.
Methods:
Male C57B1/CBA mice were exposed to MTS from two cigarettes daily, 5 days/week for 6 or 12 weeks. Mice were sacrificed immediately, or 6 weeks following the last cigarette. High density DNA microarrays were used to characterize global gene expression changes in whole lung. Microarray results were validated by Quantitative real-time RT-PCR. Further analysis of protein synthesis and function was carried out for a select set of genes by ELISA and Western blotting.
Results:
Globally, seventy nine genes were significantly differentially expressed following the exposure to MTS. These genes were associated with a number of biological processes including xenobiotic metabolism, redox balance, oxidative stress and inflammation. There was no differential gene expression in mice exposed to smoke and sampled 6 weeks following the last cigarette. Moreover, cluster analysis demonstrated that these samples clustered alongside their respective controls. We observed simultaneous up-regulation of interleukin 6 (IL-6) and its antagonist, suppressor of cytokine signalling (SOCS3) mRNA following 12 weeks of MTS exposure. Analysis by ELISA and Western blotting revealed a concomitant increase in total IL-6 antigen levels and its downstream targets, including phosphorylated signal transducer and activator of transcription 3 (Stat3), basal cell-lymphoma extra large (BCL-XL) and myeloid cell leukemia 1 (MCL-1) protein, in total lung tissue extracts. However, in contrast to gene expression, a subtle decrease in total SOCS3 protein was observed after 12 weeks of MTS exposure.
Conclusion:
Global transcriptional analysis identified a set of genes responding to MTS exposure in mouse lung. These genes returned to basal levels following smoking cessation, providing evidence to support the benefits of smoking cessation. Detailed analyses were undertaken for IL-6 and its associated pathways. Our results provide further insight into the role of these pathways in lung injury and inflammation induced by MTS.</description>
        <link>http://www.biomedcentral.com/1755-8794/2/56</link>
                <dc:creator>Sabina Halappanavar</dc:creator>
                <dc:creator>Marsha Russell</dc:creator>
                <dc:creator>Martin Stampfli</dc:creator>
                <dc:creator>Andrew Williams</dc:creator>
                <dc:creator>Carole Yauk</dc:creator>
                <dc:source>BMC Medical Genomics 2009, 2:56</dc:source>
        <dc:date>2009-08-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-8794-2-56</dc:identifier>
        <prism:publicationName>BMC Medical Genomics</prism:publicationName>
        <prism:issn>1755-8794</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>56</prism:startingPage>
        <prism:publicationDate>2009-08-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1755-8794/2/58">
        <title>Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells.  </title>
        <description>Background:
In addition to their well-documented ocular therapeutic effects, glucocorticoids (GCs) can cause sight-threatening side-effects including ocular hypertension presumably via morphological and biochemical changes in trabecular meshwork (TM) cells. In the present study, we directly compared the glucocorticoid receptor (GR) potency for dexamethasone (DEX), fluocinolone acetonide (FA) and triamcinolone acetonide (TA), examined the expression of known GR&#945; and GR&#946; isoforms, and used gene expression microarrays to compare the effects of DEX, FA, and TA on the complete transcriptome in two primary human TM cell lines.
Methods:
GR binding affinity for DEX, FA, and TA was measured by a cell-free competitive radio-labeled GR binding assay. GR-mediated transcriptional activity was assessed using the GeneBLAzer beta-lactamase reporter gene assay. Levels of GR&#945; and GR&#946; isoforms were assessed by Western blot. Total RNA was extracted from TM 86 and TM 93 cells treated with 1 &#956;M DEX, FA, or TA for 24 hr and used for microarray gene expression analysis. The microarray experiments were repeated three times. Differentially expressed genes were identified by Rosetta Resolver Gene Expression Analysis System.
Results:
The GR binding affinity (IC50) for DEX, FA, and TA was 5.4, 2.0, and 1.5 nM, respectively. These values are similar to the GR transactivation EC50 of 3.0, 0.7, and 1.5 nM for DEX, FA, and TA, respectively. All four GR&#945; translational isoforms (A-D) were expressed in TM 86 and TM 93 total cell lysates, however, the C and D isoforms were more highly expressed relative to A and B. All four GR&#946; isoforms (A-D) were also detected in TM cells, although GR&#946;-D isoform expression was lower compared to that of the A, B, or C isoforms. Microarray analysis revealed 1,968 and 1,150 genes commonly regulated by DEX, FA, and TA in TM 86 and TM 93, respectively. These genes included RGC32, OCA2, ANGPTL7, MYOC, FKBP5, SAA1 and ZBTB16. In addition, each GC specifically regulated a unique set of genes in both TM cell lines. Using Ingenuity Pathway Analysis (IPA) software, analysis of the data from TM 86 cells showed that DEX significantly regulated transcripts associated with RNA post-transcriptional modifications, whereas FA and TA modulated genes involved in lipid metabolism and cell morphology, respectively. In TM 93 cells, DEX significantly regulated genes implicated in histone methylation, whereas FA and TA altered genes associated with cell cycle and cell adhesion, respectively.
Conclusion:
Human trabecular meshwork cells in culture express all known GR&#945; and GR&#946; translational isoforms, and GCs with similar potency but subtly different chemical structure are capable of regulating common and unique gene subsets and presumably biologic responses in these cells. These GC structure-dependent effects appear to be TM cell-lineage dependent.</description>
        <link>http://www.biomedcentral.com/1755-8794/2/58</link>
                <dc:creator>Alissar Nehme</dc:creator>
                <dc:creator>Edward Lobenhofer</dc:creator>
                <dc:creator>W Stamer</dc:creator>
                <dc:creator>Jeffrey Edelman</dc:creator>
                <dc:source>BMC Medical Genomics 2009, 2:58</dc:source>
        <dc:date>2009-09-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-8794-2-58</dc:identifier>
        <prism:publicationName>BMC Medical Genomics</prism:publicationName>
        <prism:issn>1755-8794</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>58</prism:startingPage>
        <prism:publicationDate>2009-09-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
